 NEW HAVEN, Conn., Aug. 07, 2020 GLOBE NEWSWIRE -- BioXcel Therapeutics, Inc. BTI or Company Nasdaq: BTAI, a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced it will host a conference call and webcast on Friday, August 14, 2020 at 8:30 AM Eastern Time to discuss its second quarter 2020 operating and financial results. Conference Call Webcast DetailsDateTime: Friday, August 14, 2020, 8:30 AM Eastern Time Domestic: 877-407-2985 International: 201-378-4915 The webcast will be accessible under Events on the News Media page of the Companys website at 877-660-6853 International: 201-612-7415 Conference ID: 13708104 Replay available through at least August 28, 2020About BioXcel Therapeutics, Inc.BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTIs drug re-innovation approach leverages existing approved drugs andor clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTIs two most advanced clinical development programs are BXCL501, an investigational sublingual thin film formulation in development for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immunity activator in development for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immuno-oncology agents. For more information, please visit Information:BioXcel Therapeutics, Inc. Relations:John Graziano 1.646.378.2942Media:Julia Deutsch 1.646.378.2967 